Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been
widely used in the treatment of metastatic bone tumors. In addition to its inhibition of
tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies
have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain
inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung
metastasis through this study.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University